Results of Niraparib/Bevacizumab Combo in Platinum-Sensitive Recurrent Ovarian Cancer

New research reveals PD-L1 expression enhances survival in advanced ovarian cancer, linking it to homologous recombination deficiency and treatment personalization.

In season 2, episode 6 of Targeted Talks, Alexander B. Olawaiye, MD leads a discussion with Haider S. Mahdi, MD, about the modern approaches to treating cervical and endometrial cancers.

The QUILT-88 study reveals promising survival rates for advanced pancreatic cancer patients using a multimodal treatment approach, combining chemotherapy and immunotherapy.

Sarah M. Temkin, MD leads discussion with Daphne B. Stewart, MD, around targeted therapies in ovarian cancer, whether offered in the academic or community setting.

Anixa Biosciences advances CAR T-cell therapy for recurrent ovarian cancer, targeting FSHR with promising safety and efficacy in ongoing clinical trials.

Explore the innovative subcutaneous delivery of isatuximab for multiple myeloma, enhancing patient experience and treatment efficiency in the IRAKLIA study.